- Home
- MGNX vs SRBK Comparison
MGNX vs SRBK Comparison
Compare MGNX & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- SRBK
- Stock Information
- Founded
- MGNX 2000
- SRBK 1887
- Country
- MGNX United States
- SRBK United States
- Employees
- MGNX N/A
- SRBK N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- SRBK
- Sector
- MGNX Health Care
- SRBK
- Exchange
- MGNX Nasdaq
- SRBK Nasdaq
- Market Cap
- MGNX 99.7M
- SRBK 117.4M
- IPO Year
- MGNX 2013
- SRBK N/A
- Fundamental
- Price
- MGNX $1.76
- SRBK $15.14
- Analyst Decision
- MGNX Hold
- SRBK
- Analyst Count
- MGNX 5
- SRBK 0
- Target Price
- MGNX $3.25
- SRBK N/A
- AVG Volume (30 Days)
- MGNX 582.9K
- SRBK 34.9K
- Earning Date
- MGNX 08-14-2025
- SRBK 10-25-2025
- Dividend Yield
- MGNX N/A
- SRBK 1.32%
- EPS Growth
- MGNX N/A
- SRBK N/A
- EPS
- MGNX N/A
- SRBK 0.44
- Revenue
- MGNX $165,495,000.00
- SRBK $31,833,000.00
- Revenue This Year
- MGNX N/A
- SRBK N/A
- Revenue Next Year
- MGNX N/A
- SRBK N/A
- P/E Ratio
- MGNX N/A
- SRBK $34.43
- Revenue Growth
- MGNX 303.47
- SRBK 39.53
- 52 Week Low
- MGNX $0.99
- SRBK $9.84
- 52 Week High
- MGNX $5.10
- SRBK $15.22
- Technical
- Relative Strength Index (RSI)
- MGNX 57.55
- SRBK 72.40
- Support Level
- MGNX $1.69
- SRBK $14.10
- Resistance Level
- MGNX $1.87
- SRBK $15.21
- Average True Range (ATR)
- MGNX 0.12
- SRBK 0.28
- MACD
- MGNX 0.02
- SRBK 0.07
- Stochastic Oscillator
- MGNX 71.59
- SRBK 95.02
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.